CST, 95940S, BST2 (E4N3W) Rabbit Monoclonal Antibody

Monoclonal Antibody for studying BST2. Validated for WB,IHC,IHC,F. Available in 2 sizes. Highly specific and rigorously validated in-house, BST2 (E4N3W) Rabbit Monoclonal Antibody (CST #95940) is ready to ship. Product Usage Information Western Blotting: 1:1000 IHC Leica Bond: 1:400 - 1:1600 Immunohistochemistry (Paraffin): 1:200 - 1:800 Flow Cytometry (Live): 1:50 - 1:200 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody. For a carrier free (BSA and azide free) version of this product see product # 38142 . Protocol Available protocols: Western Blotting, IHC Leica Bond, Immunohistochemistry (Paraffin), Flow Cytometry (Live) Specificity / Sensitivity BST2 (E4N3W) Rabbit Monoclonal Antibody recognizes endogenous levels of total BST2 protein. This clone shows a preference for the BST2 dimer by western blot. Species Reactivity: Human Source / Purification Monoclonal antibody is produced by immunizing animals with human BST2 recombinant protein. Background BST2 (CD317, Tetherin, HM1.24) is a type II transmembrane glycoprotein functioning as a major mediator of the innate immune defense against the dissemination of enveloped viruses by tethering virion on the cell surface (1). BST2 has an N-terminal cytoplasmic tail for endocytosis and cytoskeletal signaling, a transmembrane domain, an extracellular domain containing putative disulfide bonds and coiled-coil region for homodimer formation, and a C-terminal GPI domain for membrane anchoring (2,3). Both the transmembrane domain and the GPI domain can insert either into the cell membrane or the viral envelope membrane and hold them together to prevent viral release. Some viruses encode proteins, such as HIV-1 and Vpu, respectively, to act as antagonists to counteract BST2 (2,3). BST2 is overexpressed in gastrointestinal cancers, breast cancer, lung cancer, and multiple myeloma (4-7). BST2 monoclonal antibody targeting myeloma or lung cancer cells induces cellular cytotoxicity and cell death (ADCC, antibody-dependent cell-mediated cytotoxicity). Thus, BST2 serves as a potential target for tumor immunotherapy. Alternate Names Bone marrow stromal antigen 2; bone marrow stromal cell antigen 2; BST-2; BST2; CD317; HM1.24 antigen; NPC-A-7; Tetherin Specification REACTIVITY: H SENSITIVITY: Endogenous MW (kDa): 28-40, 50-70 Source/Isotype: Rabbit IgG